Novelion Therapeutics to Announce Preliminary Fourth Quarter and Full Year 2016 Financial Results on March 15, 2017
March 13 2017 - 4:15PM
Novelion Therapeutics Inc. (NASDAQ:NVLN)
(TSX:NVLN), a biopharmaceutical company dedicated to developing new
standards of care for individuals living with rare diseases, today
announced that management will host a conference call and audio
webcast on Wednesday, March 15, 2017 at 8:30 a.m. Eastern Time to
provide a business update and review preliminary fourth quarter and
full year 2016 financial results.
To participate, please dial (866) 516-3002 (domestic) or (760)
298-5082 (international). A live webcast will be available in the
“Investors” section of Novelion’s website, www.novelion.com, and a
replay will be available for 90 days after the conclusion of the
event.
About Novelion Therapeutics Novelion
Therapeutics is a biopharmaceutical company dedicated to developing
new standards of care for individuals living with rare diseases.
Novelion has a diversified commercial portfolio through its
indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes
MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate
for the potential treatment of inherited retinal disease caused by
underlying mutations in RPE65 or LRAT genes. The company seeks to
advance its portfolio of rare disease therapies by investing in
science and clinical development.
CONTACT:
Amanda Murphy, Director, Investor & Corporate Communications
Novelion Therapeutics
857-242-5024
amanda.murphy@novelion.com
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novelion Therapeutics (NASDAQ:NVLN)
Historical Stock Chart
From Apr 2023 to Apr 2024